ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1149

A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies

Alejandro Durán-Sotuela1, Mercedes Fernández-Moreno1, Tamara Hermida-Gómez1, Sara Relaño1, Victoria Suárez-Ulloa2, vanesa Balboa-Barreiro3, Natividad Oreiro1, Jorge Vázquez-García1, FJ Blanco1 and Ignacio Rego-Pérez1, 1Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, 2Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, 3Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain

Meeting: ACR Convergence 2022

Keywords: Biomarkers, genomics, Osteoarthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Knee osteoarthritis progression is heterogeneous in the population, being the most aggresive form the rapid progressive knee osteoarthritis (RPKOA). These patients suffer a worsening of the joint in a short window of time. Previous results showed that mitochondrial DNA (mtDNA) variation modify the incidence and progression of OA, but their influence on the RPKOA is unknown. Our objectives for the present work are:

  • To find new mtDNA variants related to RPKOA to develop a predictive model
  • To find out the functional significance of these variants

Methods: In the discovery phase we used the Osteoarthritis Initiative (OAI) and in the replication phase we pooled individuals from the Cohort Hip and Cohort Knee (CHECK) and the Prospective Cohort of Osteoarthritis from A Coruña (PROCOAC) cohorts. Patients were classified as follows:

  • Rapid progressors (N Discovery=268, N Replication=107), subjects with baseline KL grade 0-1 and increase up to KL≥3 during 48-month follow-up; or baseline KL grade 2 and increase up to KL grade 4 during the follow-up
  • Non-rapid progressors (N Discovery=827, N Replication=592), subjects with the same baseline characteristics as rapid progressors, but with a slower or no evolution over time

mtDNA in the OAI was screened by in-depth sequencing. Resulting variant was analyzed in the replication phase by Sanger sequencing. Statistical approaches adjusting by confounding variables followed by a meta-analysis were applied. We developed a functional study using two types of transmitochondrial cybrids belonging to mtDNA haplogroup H, with and without the mitochondrial variant of interest.

Results: The in-depth sequencing of mtDNA revealed that mtDNA D-loop variant m.16519C showed a significantly higher frequency in the rapid-progressors group (OR=1,558;95%CI=1,148-2,113;nominal p-value=0,004; B-H corrected pvalue=0,044). These results were similar to those obtained in the replication cohort (OR=1,647;95%CI=1,013-2,678; p=0,043).

The preditive models of the OAI revealed that, regardless of the different clinical variables, the variant m.16519C was significantly associated with RPKOA (OR=1,559;95%CI=1,125-2,161; p=0,008). By contrast, in the replication phase the trend was similar but bordered on the statistical significance (OR=1,506;95%CI=0,848-2,675;p=0,162) (Table 1). The subsequent meta-analysis confirmed the significant association between this mtDNA variant and RPKOA (OR=1,58;95% CI=1,22-2,05;p=0,0027) (Figure 1).

In contrast with wildtype cybrids, those harboring the mtDNA variant showed lower expression mRNA levels of PGC-1α (p=0,0024) and FIS1 (p=0,0519), as well as a lower average cell survival under oxidative stress conditions (23,42±8,88 vs 115,7±64,1;p=0,0043). In addition, cybrind harbouring this variant alsho showed a increased mitochondrial reactive oxygen species (ROS) production (4,21±1,29 vs 2,21±1,34;p=0,014).

Conclusion: D-loop variant m.16519C increases the risk of developing a rapid progression of knee OA. Among the effects caused by this variant both mitochondrial biogenesis and fission/fusion processes, as well as cell survival under oxidative stress conditions and mitochondrial ROS production, seem to be affected.

Supporting image 1

Table 1. Binary regression model including clinical variables and mt16519C in both cohorts; A: discovery cohort ; B: replication cohort

Supporting image 2

Figure 1. Forest plot of the meta-analysis of the ORs of the two predictive models


Disclosures: A. Durán-Sotuela, None; M. Fernández-Moreno, None; T. Hermida-Gómez, None; S. Relaño, None; V. Suárez-Ulloa, None; v. Balboa-Barreiro, None; N. Oreiro, None; J. Vázquez-García, None; F. Blanco, None; I. Rego-Pérez, None.

To cite this abstract in AMA style:

Durán-Sotuela A, Fernández-Moreno M, Hermida-Gómez T, Relaño S, Suárez-Ulloa V, Balboa-Barreiro v, Oreiro N, Vázquez-García J, Blanco F, Rego-Pérez I. A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-novel-mitochondrial-variant-as-a-predictor-for-the-rapid-progressive-knee-osteoarthritis-phenotype-development-of-a-predictive-model-and-functional-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-mitochondrial-variant-as-a-predictor-for-the-rapid-progressive-knee-osteoarthritis-phenotype-development-of-a-predictive-model-and-functional-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology